English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Curbing gastrointestinal infections by defensin fragment modifications without harming commensal microbiota

MPS-Authors
/persons/resource/persons271178

Berger,  J
Electron Microscopy, Max Planck Institute for Developmental Biology, Max Planck Society;

/persons/resource/persons271181

Hipp,  K
Electron Microscopy, Max Planck Institute for Developmental Biology, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Koeninger, L., Osbelt, L., Berscheid, A., Wendler, J., Berger, J., Hipp, K., et al. (2021). Curbing gastrointestinal infections by defensin fragment modifications without harming commensal microbiota. Communications Biology, 4(1): 47. doi:10.1038/s42003-020-01582-0.


Cite as: https://hdl.handle.net/21.11116/0000-000A-5331-1
Abstract
The occurrence and spread of multidrug-resistant pathogens, especially bacteria from the ESKAPE panel, increases the risk to succumb to untreatable infections. We developed a novel antimicrobial peptide, Pam-3, with antibacterial and antibiofilm properties to counter this threat. The peptide is based on an eight-amino acid carboxyl-terminal fragment of human β-defensin 1. Pam-3 exhibited prominent antimicrobial activity against multidrug-resistant ESKAPE pathogens and additionally eradicated already established biofilms in vitro, primarily by disrupting membrane integrity of its target cell. Importantly, prolonged exposure did not result in drug-resistance to Pam-3. In mouse models, Pam-3 selectively reduced acute intestinal Salmonella and established Citrobacter infections, without compromising the core microbiota, hence displaying an added benefit to traditional broad-spectrum antibiotics. In conclusion, our data support the development of defensin-derived antimicrobial agents as a novel approach to fight multidrug-resistant bacteria, where Pam-3 appears as a particularly promising microbiota-preserving candidate.